Nuformix (FRA:1RT) Common Stock: €1.51 Mil (As of Mar. 2026)


What is Nuformix Common Stock?

Nuformix FRA:1RT Common Stock is €1.51 Mil as of Mar. 2026. The stock has 1 warning sign investors should review.

Nuformix's quarterly common stock declined from Mar. 2025 (€1.49 Mil) to Sep. 2025 (€1.15 Mil) but then increased from Sep. 2025 (€1.15 Mil) to Mar. 2026 (€1.51 Mil).

Nuformix's annual common stock increased from Mar. 2023 (€0.80 Mil) to Sep. 2024 (€0.98 Mil) and increased from Sep. 2024 (€0.98 Mil) to Sep. 2025 (€1.15 Mil).

Nuformix Common Stock Historical Data

* Premium members only.

The historical data trend for Nuformix's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nuformix Common Stock Chart

Nuformix Annual Data
Trend Dec15 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Sep24 Sep25
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.69 0.74 0.80 0.98 1.15

Nuformix Semi-Annual Data
Dec15 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Mar24 Sep24 Mar25 Sep25 Mar26
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.96 0.98 1.49 1.15 1.51

Nuformix Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of €1.51 Mil mean?
Nuformix (FRA:1RT) has a Common Stock of €1.51 Mil as of Mar. 2026. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Nuformix and its competitors.
Is Nuformix's Common Stock too high?
Nuformix's current Common Stock is €1.51 Mil.
How does Nuformix's Common Stock compare to VRTX and REGN?
Nuformix's Common Stock of €1.51 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Nuformix and its competitors. Nuformix's current Common Stock is €1.51 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nuformix stock overvalued right now?
Nuformix (FRA:1RT) has a current Common Stock of €1.51 Mil. The current Common Stock is €1.51 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Nuformix (FRA:1RT), the current Common Stock is €1.51 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nuformix Business Description

Other Exchanges NFX:UK1RT:Germany
Address C/O Arch Law Limited, 8 Bishopsgate, Huckletree Bishopsgate, London, GBR, EC2N 4BQ
Nuformix PLC is a pharmaceutical development company. It operates in pharmaceutical development, targeting unmet medical needs in fibrosis and oncology through drug repurposing. Its pipeline products include NXP001, NXP002, and NXP004. Geographically, the company operates only in the UK.